



2DR Debate: Should the Majority of People Living with HIV Be on a Two-Drug Regimen?

“Pro Standpoint”

Jürgen Rockstroh
Department of Medicine I
University Hospital Bonn, Bonn, Germany

Conflict of Interest: JKR

- **Honoraria for lectures and/or consultancies from Abivax, Galapagos, Gilead, Janssen, MSD, NPO Petrovax Pharm LLC, Theratechnologies and ViiV.**
- **Research grants from Dt. Leberstiftung, DFG, DZIF, Hectorstiftung, NEAT ID.**

Who do you trust ???



What does Dr Waters think of 2DR therapy???

Review > [Curr Opin Infect Dis.](#) 2020 Feb;33(1):28-33. doi: 10.1097/QCO.0000000000000615.

Two drugs regimens for HIV

Laura Waters ¹, Hannah Church ²

Affiliations + expand


PMID: 31834030 DOI: [10.1097/QCO.0000000000000615](#)

Abstract

Purpose of review: As the evidence for two-drug regimens (2DR) for HIV treatment accumulates and 2DR start to enter consensus guidelines, this review covers the history, rationale and current evidence for 2DR in first-line and switch settings.

Recent findings: Until recently, most evidence for 2DR was for boosted protease inhibitor-based therapies but now we have large, randomized trials to support the use of dolutegravir (DTG)-based 2DR, both for initial therapy and suppressed switch, with high efficacy and no emergent resistance at failure.

FULL TEXT LINKS



ACTIONS



SHARE




PAGE NAVIGATION

< Title & authors

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000


DTG/3TC Has Demonstrated Non-Inferior Efficacy Versus Other ART Regimens in Treatment-Naive and Treatment-Experienced PLWH

- Rapid treatment of HIV-1 infection has been associated with improved linkage to and retention in care and reduced time to virologic suppression in PLWH^{1,2}
- DTG/3TC has demonstrated non-inferior efficacy, a good safety profile, and a high barrier to resistance in treatment-naive PLWH in the GEMINI studies (vs DTG + TDF/FTC)³⁻⁵ and treatment-experienced, virologically suppressed PLWH in the TANGO (vs continuing 3- or 4-drug TAF-based regimens)⁶⁻⁸ and SALSA studies (vs continuing any current 3- or 4-drug ART regimen)⁹



^aFor participants with baseline HIV-1 RNA >500,000 c/mL: DTG + 3TC, 10/13 (77%); DTG + TDF/FTC, 12/15 (80%).¹⁰
¹ CDC. Understanding the HIV Care Continuum. 2019. ² DHHS. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>. Accessed August 12, 2021. ³ Cahn et al. *Lancet*. 2019;393:143-155. ⁴ Cahn et al. *J Acquir Immune Defic Syndr*. 2020;83:310-318. ⁵ Cahn et al. HIV Glasgow 2020; Virtual. Poster P018. ⁶ van Wyk et al. *Clin Infect Dis*. 2020;71:1920-1929. ⁷ van Wyk et al. HIV Glasgow 2020; Virtual. Slides O441. ⁸ van Wyk et al. IAS 2021; Virtual. Poster PEB164. ⁹ Libre et al. IAS 2021; Virtual. Slides OALB0303. ¹⁰ Orkin et al. CROI 2021; Virtual. Science spotlight 1991.


HIV-1 RNA <50 c/mL Was Comparable Across Baseline Disease Subgroups at Week 144



^aIncludes values for HIV-1 RNA >250,000 c/mL (DTG + 3TC, 41/51 [80%]; DTG + TDF/FTC, 37/46 [80%]), HIV-1 RNA >400,000 c/mL (DTG + 3TC, 15/18 [83%]; DTG + TDF/FTC, 19/24 [79%]), and HIV-1 RNA >500,000 c/mL (DTG + 3TC, 10/13 [77%]; DTG + TDF/FTC, 12/15 [80%]). ^bAdjusted difference for overall population (DTG + 3TC – DTG + TDF/FTC). Unadjusted difference for subgroups calculated by proportion on DTG + 3TC – proportion on DTG + TDF/FTC.

EACS Guidelines version 11.1


At EACS we do love footnotes.....



ART is recommended in all adult PLWH, irrespective of CD4 counts⁽¹⁾

Regimen	Main requirements	Additional guidance (see footnotes)
Recommended regimens		
2 NRTIs + INSTI		
ABC/3TC + DTG ABC/3TC/DTG	HLA-B*57:01 negative HBsAg negative	I (ABC: HLA-B*57:01, cardiovascular risk) II (Weight increase (DTG))
TAF/FTC/BIC		II (Weight increase (BIC, TAF))
TAF/FTC or TDF/XTC + DTG		II (Weight increase (DTG, TAF)) III (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
TAF/FTC or TDF/XTC + RAL qd or bid		II (Weight increase (RAL, TAF)) III (TDF: prodrug types. Renal and bone toxicity. TAF dosing) IV (RAL: dosing)
1 NRTI + INSTI		
XTC + DTG or 3TC/DTG	HBsAg negative HIV-VL < 500,000 copies/mL Not recommended after PrEP failure	II (Weight increase (DTG)) V (3TC/DTG not after PrEP failure)
2 NRTIs + NNRTI		
TAF/FTC or TDF/XTC + DOR or TDF/3TC/DOR		II (Weight increase (TAF)) III (TDF: prodrug types. Renal and bone toxicity. TAF dosing) VI (DOR: caveats, HIV-2)
Alternative regimens		
2 NRTIs + NNRTI		
TAF/FTC or TDF/XTC + EFV or TDF/FTC/EFV	At bedtime or 2 hours before dinner	II (Weight increase (TAF)) III (TDF: prodrug types. Renal and bone toxicity. TAF dosing) VII (EFV: neuro-psychiatric adverse events. HIV-2 or HIV-1 group 0, dosing)
TAF/FTC or TDF/XTC + RPV or TAF/FTC/RPV or TDF/FTC/RPV	CD4 count > 200 cells/ μ L HIV-VL < 100,000 copies/mL Not on gastric pH increasing agents With food	II (Weight increase (TAF)) III (TDF: prodrug types. Renal and bone toxicity. TAF dosing) VIII (RPV: HIV-2)
2 NRTIs + BIC or BIC		

At Week 48, Virologic Suppression Rates Were High in Participants With Baseline Viral Load $\geq 500,000$ c/mL



- 11/19 participants with baseline HIV-1 RNA $\geq 500,000$ c/mL had CD4+ cell count < 200 cells/mm³; 10 achieved HIV-1 RNA < 50 c/mL at Week 48 and 1 withdrew at Week 4 due to physician decision
- Median (95% CI) time to suppression for participants with baseline viral load $\geq 500,000$ c/mL was 60 (56-169) days

ITT-E missing = failure analysis: all participants in the ITT-E population, regardless of ART regimen; observed analysis: all participants with available HIV-1 RNA data, regardless of ART regimen.

^a1 (<1%) participant had missing plasma HIV-1 RNA results at baseline.

Among Participants With CVF or Baseline HBV Co-infection, No Evidence of Treatment-Emergent Resistance Was Observed

	Participants meeting CVF criteria at Week 48	Number of HIV resistance-associated mutations detected
Total population	2	0
Participants with baseline HIV-1 RNA \geq 500,000 c/mL	1	0

- Both participants meeting CVF criteria remained on DTG/3TC in study (1 participant suppressed to HIV-1 RNA <50 c/mL and 1 participant had HIV-1 RNA 70 c/mL at Week 48)
 - The participant with high baseline viral load (13,987,640 c/mL) was not suppressed at Week 24; HIV-1 RNA was 220 c/mL at Week 36 (CVF criteria met) and 63 c/mL at Week 48 followed by a retest at 48 c/mL


	Participants with baseline HBV co-infection	Number of HBV resistance-associated mutations detected
Total population	7	0
Participants with successful resistance tests	3	0

Rolle et al. IAS 2021; Virtual. Poster PEB182.

Global Status of HBV Infection

- » In 2019: 296 million people living with chronic HBV infection; majority in African and Western Pacific regions
- » 7.4% of persons with HIV also have HBV coinfection (2.7 million persons)
- » The global target of hepatitis B surface antigen prevalence of below 1% for 2020 among children younger than five years is one of the first 2020 targets of the health-related Sustainable Development Goals to be met.

Prevalence of HBV Infection in the General Population (2015)



The Lack of Effect of Prior M184V on Treatment Outcomes is Also Apparent in the Real-world Setting

Cohort	Study type	Patients on DTG + 3TC, N	M184V					
			Patients with M184V/I, n	M184V detection method, n	Time point	Patients maintaining/achieving virologic effectiveness (<50 c/mL), n or % or probability of VF	Patients with VF and M184V, n/N	VF definition
SOLAR 3D ¹ (United States)	Prospective, open-label	100	50	Historical genotype	Week 48	92% (46/50) maintained	0/50	VL ≥50 c/mL followed by VL >200 c/mL
Dat'AIDS ² (France)	Multicentre, retrospective	695	105	NR	NA	No significant difference in the probability of VF between M184V+ and M184V- groups after a median follow up of 1.2 years (p=0.81)	2/105	Confirmed VL >50c/mL, or a single VL ≥200 c/mL
ODACRE ³ (Italy)	Multicentre, observational, retrospective	556	45	NR	Week 144	NR for patients with M184V Overall population: 96.5% estimated probability of maintaining virologic suppression	2/45	Confirmed VL ≥50 c/mL, or a single VL ≥1,000 c/mL
LAMRES ⁴ (Europe)	Multicentre, observational, retrospective	533	37	Historical RNA, 29 Historical DNA, 7 Historical RNA and DNA, 1	1 year, 2 years	Probability of VF with presence vs absence of M184V: 5.4% vs 2.6% at 1 year; 9.2% vs 4.4% at 2 years (p=0.345) Higher probability of VF if M184V detected ≤5 years vs >5 years before switching to DTG + 3TC	3/37	Confirmed VL >50 c/mL, or a single VL ≥200 c/mL
ARCA ⁵ (Italy)	Observational, retrospective	126	21	Historical RNA	1 year	Overall population: 95.1% and 96.2% estimated probability of remaining free from VF in M184V+ (n=349) and M184V- (n=87) patients treated with 3TC + (bPI or RAL) 2DR	0 (2 VFs in M184V-negative group)	Confirmed VL >50 c/mL, or a single VL ≥200 c/mL
DOLLUM ^{6,7} (France)	Monocentric, observational, prospective	27	17	Historical RNA, 8 Sanger DNA, 2 NGS, 7	2 years	17 (100%) patients remained free from VF (1 patient experienced a blip)	0/17	Confirmed VL >50 c/mL
DOLAMA ⁸ (Spain)	Multicentre, observational, retrospective	177	4 (of 90 tested)	BL genotypic test	Week 48	75% (3/4) patients remained free of VF	1/4	Confirmed VL >50 c/mL

Results indicate that the presence of M184V at BL in virologically suppressed patients does not affect the virologic effectiveness of DTG + 3TC in clinical practice

TAF really that s

Heron et al. *BMC Nephrology* (2020) 21:339
<https://doi.org/10.1186/s12882-020-01981-9>

CASE REPORT

Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin

Jack E. Heron^{1*}, Mark Bloch^{2,3}, Vinay Vanguru⁴, John Saunders¹ and David

Ueapongsukkit et al.
<https://doi.org/10.1186/s12882-020-01981-9>

CASE REPORT

Tenofovir alafenamide nephrotoxicity: a case report and literature review

Thornthun Ueapongsukkit^{1*}, Saikorn Saikongkiet^{1,2}, Jiraporn Chaiyaprasit^{1,2}, Jirath Saikongkiet^{1,2}, Jiraporn Chaiyaprasit^{1,2}, Jirath Saikongkiet^{1,2}, Jiraporn Chaiyaprasit^{1,2}, Jirath Saikongkiet^{1,2}, Jiraporn Chaiyaprasit^{1,2}, Jirath Saikongkiet^{1,2}

Abstract

Background: The nucleotide reverse transcriptase inhibitor Tenofovir Alafenamide (TAF) and possesses a superior renal safety profile compared with tenofovir (TFV) and its unique pharmacokinetic characteristics, treatment with TAF is not associated with tubular accumulation of TFV. TAF is associated with a lower risk of acute kidney injury, proteinuria and renal proximal tubular dysfunction than treatment with TDF. Tenofovir-associated nephrotoxicity has been reported in clinical trials of TAF. It is unknown whether treatment with TAF causes tubular injury in proximal tubular cells and cause nephrotoxicity under certain clinical circumstances.

Case presentation: Here we report the case of a patient on stable TAF-based antiretroviral therapy who developed proximal tubulopathy when treated with gentamicin in the context of relapsed Hodgkin lymphoma. Eighteen days after commencing chemotherapy for relapsed Hodgkin lymphoma the patient presented to hospital with fevers, hypotension and renal dysfunction. She was commenced on piperacillin, tazobactam and gentamicin. Within 24 h the patient developed acute kidney injury and hypophosphataemia requiring intravenous replacement therapy. There was



Therapy

Open Access

case



Medicine®

OPEN

city in an

raithin A. McMahon, MD, PhD^a,

printsranont⁴,

reverse transcriptase inhibitor. TAF is less nephrotoxic than tenofovir disoproxil fumarate (TDF). Tenofovir causes mitochondrial dysfunction and tubular injury in proximal tubule cells. TAF's unique pharmacokinetic profile enables provision of lower concentrations reach renal tubules minimizing intracellular accumulation and associated with the histologic markers of tenofovir-associated nephrotoxicity that are seen in proximal tubule cells. Here, we report a patient with dysmorphic mitochondria on



individuals may experience tubular mitochondrial injury from lower concentrations of

filtration rate, HCV = hepatitis C virus, HIV = human immunodeficiency virus, PTC = proximal tubule cell, TDF = tenofovir disoproxil fumarate, TFV = tenofovir.

tenofovir alafenamide, tenofovir nephrotoxicity

Specific ART as risk factor for steatosis progression

- » N=301 mono-infected patients with serial Fibroscan with CAP, followed for a mean 41.8 ± 14.8 months
- » Progression of hepatic steatosis defined as development of CAP > 238 dB/m or progression of steatosis to grade 2 (CAP > 260) or 3 (CAP > 292) during follow-up




Cost reduction with 2DR in Germany

- » Descovy 30 Tablets = 516,77 Euro
- » Tivicay 30 tablets = 725,63 Euro
- » Descovy + Tivicay = 1242,40 Euro
- » Biktarvy 30 Tablets = 924,75 Euro
- » Dovato 30 Tablets = 857, 55 Euro

Increased flexibility of ART delivery is needed to meet the diverse needs of PLHIV

- PLHIV continue to face physical, emotional, and psychosocial challenges with daily oral ART¹
- These challenges have been associated with poor health outcomes including low treatment satisfaction, self-reported virologic failure, suboptimal self-rated overall health, and poor adherence^{1,2}

Percentage of PLHIV who reported challenges with their treatment*¹



*The Positive Perspectives Study 2019 was conducted across 25 countries (N=2,389). Participants were enrolled from Europe (n=1,119), North America (n=520), South Africa (n=179), Australia (n=120), Japan (n=75), Mexico (n=63), Brazil (n=58), Taiwan (n=55), Argentina (n=50), Chile (n=50), China (n=50), and South Korea (n=50)²
 ART, antiretroviral therapy

And what about the body language?



Summary

- » 2 DR (DOL/3TC) equally efficacious and no resistance development in first-line or switch therapy (says Dr Waters)
- » Less drugs promise less short and long-term toxicity
- » TAF containing 3DR therapy is associated with more weight gain
- » Cost savings possible with less drugs.....
- » Pills size becomes smaller with less drugs.....
- » 2DR therapy also available with different mode of delivery addressing patient needs and improving quality of life

- » **2DR is the ideal antiretroviral treatment option for the majority of PLWH**



Laura after the debate

